Rachel SP Riechelmann, Phd
AC Camargo Cancer Center · Head of Clinical Oncology Department · Fundacao Antonio Prudente
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rachel SP Riechelmann, Phd as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04831567 · Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine TumorsAC Camargo Cancer Center · withdrawn · Neuroendocrine Tumors · principal investigator
- Ph2NCT04168931 · Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTCAC Camargo Cancer Center · terminated · Gastric Cancer Stage IV · principal investigator
- Ph2NCT03870399 · Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive ExpressionAC Camargo Cancer Center · completed · Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.